How to differentiate Leronlimab for different indications? I.E., When LL is finally approved for an indication, be it for Covid, HIV, etc., it would likely be prescribed off-label for other maladies and probably wouldn't be covered by insurance, thereby limiting its attractiveness to some patients who otherwise would take it. So, does anyone have any ideas as to how, physically (and not via marketing), LL could be altered so as to be disease-specific? If that's possible, then it would open the potential for partnering with other pharma on a disease-specific basis.